Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Eli Lilly and Company |
---|---|
Information provided by: | Eli Lilly and Company |
ClinicalTrials.gov Identifier: | NCT00071136 |
This is a Phase 2 study of pemetrexed and gemcitabine chemotherapy given once every 14 days to patients with advanced stage non-small cell lung cancer.
This treatment is for patients that have not received any prior chemotherapy treatment for lung cancer. The primary goal is to find out if the tumor gets smaller or disappears with this treatment.
Condition | Intervention | Phase |
---|---|---|
Lung Neoplasms |
Drug: pemetrexed Drug: gemcitabine |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase 1/2 Dose-Escalating Study of Biweekly Alimta and Gemcitabine in Patients With Advanced Cancer |
Estimated Enrollment: | 48 |
Study Start Date: | December 2003 |
Estimated Study Completion Date: | August 2006 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Florida | |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY(1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC-GMT - 5 hours, EST), or speak with your personal physician. | |
Ft. Myers, Florida, United States | |
United States, Minnesota | |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY(1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC-GMT - 5 hours, EST), or speak with your personal physician. | |
Minneapolis, Minnesota, United States | |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY(1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC-GMT - 5 hours, EST), or speak with your personal physician. | |
Marshfield, Minnesota, United States | |
United States, New York | |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY(1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC-GMT - 5 hours, EST), or speak with your personal physician. | |
Rochester, New York, United States | |
United States, Texas | |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY(1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC-GMT - 5 hours, EST), or speak with your personal physician. | |
Dallas, Texas, United States |
Study Director: | Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) | Eli Lilly and Company |
Study ID Numbers: | 7221, H3E-US-JMGC |
Study First Received: | October 13, 2003 |
Last Updated: | January 24, 2007 |
ClinicalTrials.gov Identifier: | NCT00071136 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Thoracic Neoplasms Antimetabolites Immunologic Factors Folic Acid Antagonists Antiviral Agents Immunosuppressive Agents Folic Acid Pemetrexed |
Respiratory Tract Diseases Radiation-Sensitizing Agents Lung Neoplasms Lung Diseases Non-small Cell Lung Cancer Gemcitabine Carcinoma, Non-Small-Cell Lung |
Thoracic Neoplasms Antimetabolites Anti-Infective Agents Respiratory Tract Neoplasms Antimetabolites, Antineoplastic Immunologic Factors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Physiological Effects of Drugs Enzyme Inhibitors Folic Acid Antagonists Immunosuppressive Agents |
Antiviral Agents Pharmacologic Actions Pemetrexed Neoplasms Neoplasms by Site Radiation-Sensitizing Agents Respiratory Tract Diseases Lung Neoplasms Therapeutic Uses Lung Diseases Gemcitabine |